Acute graft-versus-host disease: Are we close to bringing the bench to the bedside?

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 3, 2013, Pages 285-292

  Sung, Anthony D ^a   Chao, Nelson J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AHSCT; allogeneic hematopoietic stem cell transplant; calcineurin inhibitors; CCR5 antagonists; extracorporeal photopheresis; graft versus host disease; gut decontamination; GVHD; immunosuppression; pathophysiology; prevention; T cell depletion; treatment

Indexed keywords

BECLOMETASONE; CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; ETANERCEPT; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; MARAVIROC; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PSORALEN; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL EXPANSION; CELL MIGRATION; CYTOKINE RELEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PUVA; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE INJURY;

AHSCT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT; CALCINEURIN INHIBITORS; CCR5 ANTAGONISTS; EXTRACORPOREAL PHOTOPHERESIS; GRAFT-VERSUS-HOST DISEASE; GUT DECONTAMINATION; GVHD; IMMUNOSUPPRESSION; PATHOPHYSIOLOGY; PREVENTION; T-CELL DEPLETION; TREATMENT;

CALCINEURIN; CELL PROLIFERATION; CYTOKINES; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; PHOTOPHERESIS; RECEPTORS, CCR5; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84889632238     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.10.009     Document Type: Review

References (83)

1. M. Jagasia, M. Arora, and M.E. Flowers Risk factors for acute GVHD and survival after hematopoietic cell transplantation Blood 119 2012 296 307
2. M.C. Pasquini, and Z. Wang Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides http://www.cibmtr.org 2011 6/25/12 A.D.
3. L.A. Welniak, B.R. Blazar, and W.J. Murphy Immunobiology of allogeneic hematopoietic stem cell transplantation Annu Rev Immunol 25 2007 139 170
4. R. Zeiser, O. Penack, and E. Holler Danger signals activating innate immunity in graft-versus-host disease J Mol Med (Berl) 89 2011 833 845
5. G.R. Hill, J.M. Crawford, and K.R. Cooke Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines Blood 90 1997 3204 3213
6. W.D. Shlomchik, M.S. Couzens, and C.B. Tang Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science 285 1999 412 415
7. C.C. Matte, J. Liu, and J. Cormier Donor APCs are required for maximal GVHD but not for GVL Nat Med 10 2004 987 992
8. S.J. Lee, J. Klein, and M. Haagenson High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation Blood 110 2007 4576 4583
9. J.L. Ferrara, J.E. Levine, and P. Reddy Graft-versus-host disease Lancet 373 2009 1550 1561
10. E. Goulmy, R. Schipper, and J. Pool Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation N Engl J Med 334 1996 281 285
11. B. Kwon Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease Exp Mol Med 42 2010 675 683
12. Y. Zhang, G. Joe, and E. Hexner Host-reactive CD8+ memory stem cells in graft-versus-host disease Nat Med 11 2005 1299 1305
13. B.J. Chen, D. DeOliveira, and X. Cui Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse Blood 109 2007 3115 3123
14. T. Yi, Y. Chen, and L. Wang Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease Blood 114 2009 3101 3112
15. C.A. Wysocki, A. Panoskaltsis-Mortari, and B.R. Blazar Leukocyte migration and graft-versus-host disease Blood 105 2005 4191 4199
16. S. Dutt, J. Ermann, and D. Tseng L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease Blood 106 2005 4009 4015
17. L.A. Palmer, G.E. Sale, and J.I. Balogun Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease Biol Blood Marrow Transplant 16 2010 311 319
18. W. Weninger, and U.H. von Andrian Chemokine regulation of naive T cell traffic in health and disease Semin Immunol 15 2003 257 270
19. R. Varona, V. Cadenas, and L. Gomez CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses Blood 106 2005 18 26
20. M.Y. Braun, B. Lowin, and L. French Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease J Exp Med 183 1996 657 661
21. C. Schmaltz, O. Alpdogan, and B.J. Kappel T cells require TRAIL for optimal graft-versus-tumor activity Nat Med 8 2002 1433 1437
22. A.D. Hess Reconstitution of self-tolerance after hematopoietic stem cell transplantation Immunol Res 47 2010 143 152
23. G.A. Hollander, B. Widmer, and S.J. Burakoff Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease J Immunol 152 1994 1609 1617
24. A.J. Beres, D. Haribhai, and A.C. Chadwick CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity J Immunol 189 2012 464 474
25. V. Rowe, T. Banovic, and K.P. MacDonald Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation Blood 108 2006 2485 2492
26. M.S. von Bergwelt-Baildon, R.H. Vonderheide, and B. Maecker Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application Blood 99 2002 3319 3325
27. D.B. Miklos, H.T. Kim, and E. Zorn Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors Blood 103 2004 353 359
28. A.P. Iori, G.F. Torelli, and M.S. De Propris B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation Transplantation 85 2008 386 390
29. S. Sarantopoulos, K.E. Stevenson, and H.T. Kim Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease Blood 113 2009 3865 3874
30. I.F. Khouri, P. McLaughlin, and R.M. Saliba Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood 111 2008 5530 5536
31. K.R. Schultz, J. Paquet, and S. Bader Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease Bone Marrow Transplant 16 1995 289 295
32. H. Li, A.J. Demetris, and J. McNiff Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction J Immunol 188 2012 3804 3811
33. M.E. Flowers, Y. Inamoto, and P.A. Carpenter Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria Blood 117 2011 3214 3219
34. M.E. Flowers, M.S. Pepe, and G. Longton Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation Br J Haematol 74 1990 492 496
35. J.J. van Rood, F.R. Loberiza Jr., and M.J. Zhang Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling Blood 99 2002 1572 1577
36. E. Gluckman, V. Rocha, and A. Boyer-Chammard Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group N Engl J Med 337 1997 373 381
37. M. Mielcarek, P.J. Martin, and W. Leisenring Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756 762
38. A.M. Dickinson, P.G. Middleton, and V. Rocha Genetic polymorphisms predicting the outcome of bone marrow transplants Br J Haematol 127 2004 479 490
39. P. Svenberg, J. Mattsson, and O. Ringden Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism Bone Marrow Transplant 44 2009 757 763
40. B.R. Dey, S. McAfee, and C. Colby Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation Biol Blood Marrow Transplant 9 2003 320 329
41. P. Bader, H. Kreyenberg, and W. Hoelle Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 22 2004 1696 1705
42. D.W. van Bekkum, J. Roodenburg, and P.J. Heidt Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora J Natl Cancer Inst 52 1974 401 404
43. D.W. Beelen, A. Elmaagacli, and K.D. Muller Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long-term follow-up of an open-label prospective randomized trial Blood 93 1999 3267 3275
44. T. Hahn, P.L. McCarthy Jr., and M.J. Zhang Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia J Clin Oncol 26 2008 5728 5734
45. S. Paczesny, T.M. Braun, and J.E. Levine Elafin is a biomarker of graft-versus-host disease of the skin Sci Transl Med 2 2010 13ra2
46. J.L. Ferrara, A.C. Harris, and J.K. Greenson Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease Blood 118 2011 6702 6708
47. J.E. Levine, B.R. Logan, and J. Wu Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study Blood 119 2012 3854 3860
48. D.E. Uphoff Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow Proc Soc Exp Biol Med 99 1958 651 653
49. R. Storb, J.H. Antin, and C. Cutler Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant 16 2010 S18 S27
50. B.L. Laskin, J. Goebel, and S.M. Davies Small vessels, big trouble in the kidneys and beyond: Hematopoietic stem cell transplantation-associated thrombotic microangiopathy Blood 118 2011 1452 1462
51. R. Wong, G.Z. Beguelin, and M. de Lima Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation Br J Haematol 122 2003 128 134
52. C. Cutler, and J.H. Antin Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: An update Curr Opin Hematol 17 2010 500 504
53. R.A. Nash, L. Johnston, and P. Parker A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 11 2005 495 505
54. L. Luznik, and E.J. Fuchs High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation Immunol Res 47 2010 65 77
55. J.E. Wagner, J.S. Thompson, and S.L. Carter Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): A multi-centre, randomised phase II-III trial Lancet 366 2005 733 741
56. R.T. Mitsuyasu, R.E. Champlin, and R.P. Gale Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial Ann Intern Med 105 1986 20 26
57. D.A. Rizzieri, L.P. Koh, and G.D. Long Partially matched, nonmyeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution J Clin Oncol 25 2007 690 697
58. D.R. Couriel, R.M. Saliba, and S. Giralt Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Biol Blood Marrow Transplant 10 2004 178 185
59. R. Reshef, S.M. Luger, and E.O. Hexner Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease N Engl J Med 367 2012 135 145
60. J.H. Antin, D. Weisdorf, and D. Neuberg Interleukin-1 blockade does not prevent acute graft-versus-host disease: Results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation Blood 100 2002 3479 3482
61. M. Hamadani, C.C. Hofmeister, and B. Jansak Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation Biol Blood Marrow Transplant 14 2008 783 789
62. K.M. Sullivan, K.J. Kopecky, and J. Jocom Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation N Engl J Med 323 1990 705 712
63. E.C. Guinan, V.A. Boussiotis, and D. Neuberg Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 340 1999 1704 1714
64. L.A. Kuzmina, N.A. Petinati, and E.N. Parovichnikova Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease - a phase II study Stem Cells Int 2012 2012 968213
65. E. Thomas, R. Storb, and R.A. Clift Bone-marrow transplantation N Engl J Med 292 1975 832 843 895-902
66. M.L. MacMillan, D.J. Weisdorf, and J.E. Wagner Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems Biol Blood Marrow Transplant 8 2002 387 394
67. K. Sullivan Graft-vs-host disease K.G. Blume, S.J. Forman, F.R. Appelbaum, Thomas' hematopoietic cell transplantation 2004 Blackwell Publishing Oxford, UK 635 664
68. C.G. Brunstein, J.S. Miller, and Q. Cao Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics Blood 117 2011 1061 1070
69. P. Perfetti, P. Carlier, and P. Strada Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD Bone Marrow Transplant 42 2008 609 617
70. P.J. Shaughnessy, B.J. Bolwell, and B.K. van Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation Bone Marrow Transplant 45 2010 1068 1076
71. P.J. Shaughnessy, C. Bachier, and M. Grimley Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease Biol Blood Marrow Transplant 11 2005 188 193
72. J. Bolanos-Meade, D.A. Jacobsohn, and J. Margolis Pentostatin in steroid-refractory acute graft-versus-host disease J Clin Oncol 23 2005 2661 2668
73. T. Furlong, W. Leisenring, and R. Storb Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease Biol Blood Marrow Transplant 8 2002 206 212
74. D.M. Hockenbery, S. Cruickshank, and T.C. Rodell A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease Blood 109 2007 4557 4563
75. P. Kebriaei, L. Isola, and E. Bahceci Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease Biol Blood Marrow Transplant 15 2009 804 811
76. K. Le Blanc, F. Frassoni, and L. Ball Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study Lancet 371 2008 1579 1586
77. C. Bucher, L. Koch, and C. Vogtenhuber IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation Blood 114 2009 5375 5384
78. A.M. Hanash, L.W. Kappel, and N.L. Yim Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL Blood 118 2011 446 455
79. L. Wang, R. Tao, and W.W. Hancock Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance Immunol Cell Biol 87 2009 195 202
80. P.A. Taylor, A. Panoskaltsis-Mortari, and G.J. Freeman Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM) Blood 105 2005 3372 3380
81. W.H. Kwan, D. Hashimoto, and E. Paz-Artal Antigen-presenting cell-derived complement modulates graft-versus-host disease J Clin Invest 122 2012 2234 2238
82. D. Hashimoto, A. Chow, and M. Greter Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation J Exp Med 208 2011 1069 1082
83. C. Ippoliti, R. Champlin, and N. Bugazia Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies J Clin Oncol 15 1997 3350 3354